UnknownPhase 2

Weekly Use of Teriparatide to Accelerate Healing of Distal Radius Fracture

80 participantsStarted 2021-06-01

Plain-language summary

The purpose of this study is to examine the effect of weekly dosing strategy on fracture healing.

Age range45 Years – 75 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Combine other physical diseases, including diabetes, severe hypertension, autoimmune diseases, heart, liver and kidney diseases, malignant tumors, mental illnesses, and other diseases that doctors believe may affect the healing process.
✕. In addition to primary osteoporosis, any disease affecting bone metabolism or treatment response, including serum PTH\>65pg/ml, 25-hydroxyvitamin D\<20ng/ml, alkaline phosphatase\>135U/L, history of bone tumor, Paget disease, history of radiotherapy
✕. The fracture site has a history of trauma or surgery, affecting the function of the wrist or forearm
✕. Those who are allergic to PTH or any excipients
✕. Currently receiving anti-osteoporosis treatment or receiving other anti-osteoporosis treatment during the trial
✕. Contraindication of teriparatide including hyperparathyroidism, severe renal insufficiency, hypercalcemia, etc.

The median time of radiographic healing

Timeframe: 0-14 weeks

NCT IDNCT04473989

SponsorPeking University Third Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-01

Junxiong Zhu, M.D.

Who can participate

Age range45 Years – 75 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Combine other physical diseases, including diabetes, severe hypertension, autoimmune diseases, heart, liver and kidney diseases, malignant tumors, mental illnesses, and other diseases that doctors believe may affect the healing process.
✕. In addition to primary osteoporosis, any disease affecting bone metabolism or treatment response, including serum PTH\>65pg/ml, 25-hydroxyvitamin D\<20ng/ml, alkaline phosphatase\>135U/L, history of bone tumor, Paget disease, history of radiotherapy
✕. The fracture site has a history of trauma or surgery, affecting the function of the wrist or forearm
✕. Those who are allergic to PTH or any excipients
✕. Currently receiving anti-osteoporosis treatment or receiving other anti-osteoporosis treatment during the trial
✕. Contraindication of teriparatide including hyperparathyroidism, severe renal insufficiency, hypercalcemia, etc.